期刊
NUCLEAR MEDICINE AND BIOLOGY
卷 36, 期 6, 页码 687-692出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.nucmedbio.2009.04.007
关键词
Sentinel lymph node biopsy; Radiopharmaceutical; [Tc-99m]DTPA-mannosyl-dextran; Lymphoseek; Molecular imaging; Breast cancer; 2-Day protocol
资金
- National Cancer Institute [R21-CA097643]
Lymphoseek is a receptor-binding radiopharmaceutical specifically designed for sentinel lymph node (SLN) mapping. We conducted a clinical trial which measured the injection site clearance and sentinel lymph node accumulation after a single intradermal injection of Lymphoseek or unfiltered [Tc-99m]sulfur colloid (TcSC) using a 2-day protocol for SLN mapping of breast cancer. Eleven patients with breast cancer participated in this study. Five patients received an intradermal administration of 1.0 nmol of Tc-99m-labeled Lymphoseek; SLN mapping was performed on four subjects within 19 to 27 h. Six subjects received an intradermal administration of TcSC; SLN mapping was performed on five subjects within 18 to 26 h. Lymphoseek exhibited a significantly (P<001) faster injection site clearance than TcSC. The mean Lymphoseek clearance half-time was 2.18 +/- 1.09 h compared to 57.4 +/- 92.8 h for TcSC. The mean sentinel lymph node uptake of Lymphoseek (1.5 +/- 1.7%) and TcSC (3.5 +/- 3.1%) was statistically equivalent (P=.213). When an intradermal injection is employed, Lymphoseek demonstrated faster injection site clearance than unfiltered [Tc-99m]sulfur colloid and persistent SLN accumulation for at least 24 h. (C) 2009 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据